Brian Elsbernd - Nov 26, 2024 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Chief Compliance/Legal Officer
Signature
/s/ Brian Elsbernd
Stock symbol
CPRX
Transactions as of
Nov 26, 2024
Transactions value $
-$46,104
Form type
4
Date filed
11/29/2024, 08:08 PM
Previous filing
Nov 25, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common Stock, par value $0.001 per share Options Exercise $201K +50.2K +40.38% $4.01 175K Nov 26, 2024 Direct
transaction CPRX Common Stock, par value $0.001 per share Sale -$201K -9.3K -5.32% $21.65 165K Nov 26, 2024 Direct F1
transaction CPRX Common Stock, par value $0.001 per share Options Exercise $39.1K +9.76K +5.9% $4.01 175K Nov 26, 2024 Direct
transaction CPRX Common Stock, par value $0.001 per share Sale -$85.4K -3.96K -2.26% $21.58 171K Nov 26, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to Purchase Common Stock Options Exercise $0 -50.2K -4.35% $0.00 1.1M Nov 26, 2024 Common Stock 50.2K $4.01 Direct F2
transaction CPRX Options to Purchase Common Stock Options Exercise $0 -9.76K -0.88% $0.00 1.1M Nov 26, 2024 Common Stock 9.76K $4.01 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold for tax purposes and to pay the exercise price of the options and not as a result of a disagreement with the Company. Mr. Elsbernd remains an executive officer of the Company.
F2 Options vested in three annual tranches beginning on January 2, 2019.